WO2008037700A3 - Methods for breast cancer prognosis - Google Patents
Methods for breast cancer prognosis Download PDFInfo
- Publication number
- WO2008037700A3 WO2008037700A3 PCT/EP2007/060143 EP2007060143W WO2008037700A3 WO 2008037700 A3 WO2008037700 A3 WO 2008037700A3 EP 2007060143 W EP2007060143 W EP 2007060143W WO 2008037700 A3 WO2008037700 A3 WO 2008037700A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- breast cancer
- methods
- prognosis
- patients
- cancer prognosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer in untreated breast cancer patients. More specific, the present invention relates to the prognosis of breast cancer based on measurements of the expression levels of marker genes in tumor samples of breast cancer patients. Marker genes are disclosed which allow for an accurate prognosis of breast cancer in patients having node negative, fast proliferating breast cancer.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/441,748 US20090311700A1 (en) | 2006-09-27 | 2007-09-25 | Methods for Breast Cancer Prognosis |
EP07820546.5A EP2066805B1 (en) | 2006-09-27 | 2007-09-25 | Methods for breast cancer prognosis |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06020209 | 2006-09-27 | ||
EP06020209.0 | 2006-09-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008037700A2 WO2008037700A2 (en) | 2008-04-03 |
WO2008037700A3 true WO2008037700A3 (en) | 2008-07-03 |
Family
ID=38926441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/060143 WO2008037700A2 (en) | 2006-09-27 | 2007-09-25 | Methods for breast cancer prognosis |
Country Status (3)
Country | Link |
---|---|
US (1) | US20090311700A1 (en) |
EP (2) | EP3135773A1 (en) |
WO (1) | WO2008037700A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7960114B2 (en) | 2007-05-02 | 2011-06-14 | Siemens Medical Solutions Usa, Inc. | Gene signature of early hypoxia to predict patient survival |
US20080286273A1 (en) * | 2007-05-02 | 2008-11-20 | Siemens Medical Solutions Usa, Inc. | Knowledge-Based Proliferation Signatures and Methods of Use |
EP2389448A1 (en) * | 2009-01-21 | 2011-11-30 | Universita' Degli Studi Di Padova | Prognosis of breast cancer patients by monitoring the expression of two genes |
US8597885B2 (en) | 2009-01-28 | 2013-12-03 | University Of Notre Dame | Accelerated progression relapse test |
US20120149594A1 (en) * | 2010-12-10 | 2012-06-14 | Nuclea Biotechnologies, Inc. | Biomarkers for prediction of breast cancer |
JP2014221065A (en) * | 2014-07-07 | 2014-11-27 | ユニヴァーシタ デグリ ステューディ ディ パドヴァ | Prognosis of breast cancer patient by observation of expression of two genes |
EP3202913B1 (en) * | 2016-02-08 | 2019-01-30 | King Faisal Specialist Hospital And Research Centre | A set of genes for use in a method of predicting the likelihood of a breast cancer patient's survival |
EP3260552A1 (en) * | 2016-06-20 | 2017-12-27 | Istituto Europeo di Oncologia (IEO) | Methods and kits comprising gene signatures for stratifying breast cancer patients |
KR101950717B1 (en) * | 2016-11-23 | 2019-02-21 | 주식회사 젠큐릭스 | Methods for predicting effectiveness of chemotherapy for breast cancer patients |
KR102422610B1 (en) * | 2020-05-12 | 2022-07-18 | 서울대학교 산학협력단 | Methods for predicting prognosis in early breast cancer patients |
CN117607442B (en) * | 2024-01-23 | 2024-04-16 | 杭州华得森生物技术有限公司 | Marker for predicting breast cancer immunotherapy effect, kit and application |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
US7354705B2 (en) | 2003-01-30 | 2008-04-08 | Schering Corporation | Methods for cancer prognosis and diagnosis |
JP4579246B2 (en) * | 2003-09-24 | 2010-11-10 | オンコセラピー・サイエンス株式会社 | How to diagnose breast cancer |
ATE550440T1 (en) * | 2004-11-05 | 2012-04-15 | Genomic Health Inc | MOLECULAR INDICATORS FOR BREAST CANCER PROGNOSIS AND PREDICTION OF TREATMENT RESPONSE |
WO2006084272A2 (en) * | 2005-02-04 | 2006-08-10 | Rosetta Inpharmatics Llc | Methods of predicting chemotherapy responsiveness in breast cancer patients |
-
2007
- 2007-09-25 US US12/441,748 patent/US20090311700A1/en not_active Abandoned
- 2007-09-25 EP EP16180991.8A patent/EP3135773A1/en not_active Withdrawn
- 2007-09-25 EP EP07820546.5A patent/EP2066805B1/en not_active Not-in-force
- 2007-09-25 WO PCT/EP2007/060143 patent/WO2008037700A2/en active Application Filing
Non-Patent Citations (6)
Title |
---|
LUBOSHITS GALIA ET AL: "Elevated expression of the CC chemokine Regulated on Activation, Normal T Cell Expressed and Secreted (RANTES) in advanced breast carcinoma", CANCER RESEARCH, vol. 59, no. 18, 15 September 1999 (1999-09-15), pages 4681 - 4687, XP002467110, ISSN: 0008-5472 * |
NIWA Y ET AL: "Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH FEB 2001, vol. 7, no. 2, February 2001 (2001-02-01), pages 285 - 289, XP002467109, ISSN: 1078-0432 * |
NUYTEN DIMITRY S A ET AL: "Gene expression signatures to predict the development of metastasis in breast cancer.", BREAST DISEASE 2006-2007, vol. 26, 23 April 2007 (2007-04-23), pages 149 - 156, XP009095049, ISSN: 0888-6008 * |
POCKAJ BARBARA A ET AL: "Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer.", ANNALS OF SURGICAL ONCOLOGY MAR 2004, vol. 11, no. 3, March 2004 (2004-03-01), pages 328 - 339, XP002467000, ISSN: 1068-9265 * |
VEER VAN 'T L ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 415, 2002, pages 530 - 536, XP002404599, ISSN: 0028-0836 * |
WANG Y ET AL: "Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 365, no. 9460, 19 February 2005 (2005-02-19), pages 671 - 679, XP004758006, ISSN: 0140-6736 * |
Also Published As
Publication number | Publication date |
---|---|
EP2066805A2 (en) | 2009-06-10 |
WO2008037700A2 (en) | 2008-04-03 |
EP2066805B1 (en) | 2016-07-27 |
EP3135773A1 (en) | 2017-03-01 |
US20090311700A1 (en) | 2009-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008037700A3 (en) | Methods for breast cancer prognosis | |
WO2008006517A3 (en) | Prediction of breast cancer response to taxane-based chemotherapy | |
EP2420837A3 (en) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method | |
WO2007095644A3 (en) | Reagents and methods for cancer prognosis and pathological staging | |
WO2009111643A3 (en) | Microrna markers for recurrence of colorectal cancer | |
WO2004065583A3 (en) | Gene expression markers for breast cancer prognosis | |
CL2007003649A1 (en) | An anti-cd70 human monoclonal antibody associated molecule conjugate; composition comprising the antibody-associated molecule conjugate; method of inhibiting the growth of tumor cells expressing cd70. | |
WO2006012646A3 (en) | Amacr cancer markers | |
WO2010045318A3 (en) | Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type | |
WO2007109236A8 (en) | Microrna fingerprints during human megakaryocytopoiesis | |
EA200801046A1 (en) | NON-INVASIVE METHOD FOR IDENTIFYING TRANSITIONAL CELL CARCINOMA OF URINARY BUBBLE IN VITRO | |
WO2008117314A3 (en) | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
NZ705645A (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
WO2010051314A3 (en) | Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations | |
WO2009019368A3 (en) | Method for the assay of liver fatty acid-binding protein, ace and ca19-9 for the in vitro diagnosis of colorectal cancer | |
WO2006133923A3 (en) | Diagnosis, prognosis and prediction of recurrence of breast cancer | |
TR201907389T4 (en) | Method for the prognosis and treatment of bone cancer with metastases caused by breast cancer. | |
WO2008031839A3 (en) | Gene expression signature for the prognosis, diagnosis, and therapy of prostate cancer and uses thereof | |
WO2008115750A3 (en) | Compositions and methods for the treatment of cancer | |
MX2009013646A (en) | Methods of diagnosing and treating cancer. | |
WO2013083098A3 (en) | Method of determination of cancer cell drug sensitivity towards aurora kinase inhibitors | |
WO2011112845A3 (en) | Methods and compositions related to a multi-methylation assay to predict patient outcome | |
WO2009019370A3 (en) | Apolipoprotein aii assay method for the in vitro diagnosis of colorectal cancer | |
WO2007133551A3 (en) | Method for testing drug sensitivity in solid tumors by quantifying mrna expression in thinly-sliced tumor tissue | |
WO2009034481A3 (en) | Methylation biomarker for early detection of gastric cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07820546 Country of ref document: EP Kind code of ref document: A2 |
|
REEP | Request for entry into the european phase |
Ref document number: 2007820546 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007820546 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12441748 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |